{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ABCA4-Related+Retinopathies",
    "query": {
      "condition": "ABCA4-Related Retinopathies"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ABCA4-Related+Retinopathies&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T10:23:06.360Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04239625",
      "title": "Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Stargardt Macular Degeneration",
        "Stargardt Macular Dystrophy",
        "Autosomal Recessive Stargardt Disease 1 (ABCA4-related)"
      ],
      "interventions": [
        {
          "name": "ALK-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkeus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "8 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2019-12-20",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04239625"
    },
    {
      "nct_id": "NCT01736293",
      "title": "Natural History of Eye Diseases Related to ABCA4 Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Degeneration",
        "ABCA4-Related Retinopathies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-10-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736293"
    },
    {
      "nct_id": "NCT01920867",
      "title": "Stem Cell Ophthalmology Treatment Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Disease",
        "Macular Degeneration",
        "Hereditary Retinal Dystrophy",
        "Optic Nerve Disease",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "RB (Retrobulbar)",
          "type": "PROCEDURE"
        },
        {
          "name": "ST (Subtenon)",
          "type": "PROCEDURE"
        },
        {
          "name": "IV (Intravenous)",
          "type": "PROCEDURE"
        },
        {
          "name": "IVIT (Intravitreal)",
          "type": "PROCEDURE"
        },
        {
          "name": "IO (Intraocular)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "MD Stem Cells",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2012-08",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 1,
      "location_summary": "Westport, Connecticut",
      "locations": [
        {
          "city": "Westport",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01920867"
    },
    {
      "nct_id": "NCT07502664",
      "title": "Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinitis Pigmentosa",
        "Stargardt Macular Dystrophy",
        "Stargardt Disease",
        "Geographic Atrophy From Age-related Macular Degeneration",
        "X-linked Retinoschisis",
        "Retinal Dystrophies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ray Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-02-19",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07502664"
    },
    {
      "nct_id": "NCT06375239",
      "title": "Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinitis Pigmentosa",
        "Choroideremia",
        "Stargardt Macular Dystrophy",
        "Stargardt Disease",
        "Geographic Atrophy from Age-related Macular Degeneration",
        "X-lined Retinoschisis",
        "Retinal Dystrophies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ray Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2024-04-05",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06375239"
    },
    {
      "nct_id": "NCT02410122",
      "title": "The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Stargardt Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-12",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2018-08-03",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Dallas, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410122"
    },
    {
      "nct_id": "NCT02402660",
      "title": "Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Stargardt Macular Degeneration",
        "Stargardt Macular Dystrophy",
        "Autosomal Recessive Stargardt Disease 1 (ABCA4-related)"
      ],
      "interventions": [
        {
          "name": "ALK-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkeus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "8 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2015-08",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02402660"
    },
    {
      "nct_id": "NCT07594236",
      "title": "Phase 1 Study of C.001 in Retinal Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Geographic Atrophy",
        "Stargardt Disease",
        "RPE-mediated Maculopathy",
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cellio Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2026-04-07",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Palo Alto, California • Sacramento, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07594236"
    },
    {
      "nct_id": "NCT06467344",
      "title": "Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Cone Rod Dystrophy",
        "Juvenile Macular Degeneration",
        "Stargardt Disease 1"
      ],
      "interventions": [
        {
          "name": "ACDN-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascidian Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-06-11",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Gainesville, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06467344"
    },
    {
      "nct_id": "NCT06319872",
      "title": "The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Use Disorder",
        "Retinal Dystrophies",
        "Age-Related Macular Degeneration",
        "Retinitis Pigmentosa",
        "Stargardt Disease"
      ],
      "interventions": [
        {
          "name": "Oral disulfiram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-05-19",
      "completion_date": "2029-05-19",
      "has_results": false,
      "last_update_posted_date": "2025-09-29",
      "last_synced_at": "2026-09-13T10:23:06.360Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06319872"
    }
  ]
}